Post-earnings recap
Reported
Wed, Feb 26, 2014
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Nektar Therapeutics reported a significant EPS miss, but the stock still rose by 2.24%. This increase may reflect investor optimism about the company's pipeline and future potential, despite the lack of revenue data and guidance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.41 | N/A | -153.09% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the challenges faced during the quarter. They emphasized their commitment to pipeline development without providing future guidance.
Management did not provide specific guidance for the upcoming quarters.
The focus remains on advancing their pipeline despite the EPS miss.